USD
+$0.00
(+0.00%
)At Close (As of Sep 18, 2025)
$21.42M
Market Cap
-
P/E Ratio
-0.66
EPS
$1.03
52 Week High
$0.04
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $178M |
Total Revenue | $178M |
Cost Of Revenue | $70K |
Costof Goods And Services Sold | $70K |
Operating Income | -$69M |
Selling General And Administrative | $81M |
Research And Development | $149M |
Operating Expenses | $247M |
Investment Income Net | - |
Net Interest Income | $3.2M |
Interest Income | $6.6M |
Interest Expense | $3.3M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $11M |
Income Before Tax | -$67M |
Income Tax Expense | $3.6M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$71M |
Comprehensive Income Net Of Tax | - |
Ebit | -$64M |
Ebitda | -$53M |
Net Income | -$71M |
Field | Value (USD) |
---|---|
Total Assets | $246M |
Total Current Assets | $188M |
Cash And Cash Equivalents At Carrying Value | $91M |
Cash And Short Term Investments | $91M |
Inventory | $7.3M |
Current Net Receivables | $16M |
Total Non Current Assets | $58M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $3.9M |
Intangible Assets Excluding Goodwill | $3.9M |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $60M |
Other Current Assets | $13M |
Other Non Current Assets | - |
Total Liabilities | $234M |
Total Current Liabilities | $65M |
Current Accounts Payable | $8.7M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $9.4M |
Total Non Current Liabilities | $170M |
Capital Lease Obligations | $24M |
Long Term Debt | $50M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $74M |
Other Current Liabilities | $34M |
Other Non Current Liabilities | $4.3M |
Total Shareholder Equity | $12M |
Treasury Stock | - |
Retained Earnings | -$1.1B |
Common Stock | $2.1M |
Common Stock Shares Outstanding | $252M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$73M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $11M |
Capital Expenditures | $2.7M |
Change In Receivables | - |
Change In Inventory | -$7.4M |
Profit Loss | - |
Cashflow From Investment | -$59M |
Cashflow From Financing | $79M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$71M |
Field | Value (USD) |
---|---|
Gross Profit | $178M |
Total Revenue | $178M |
Cost Of Revenue | $70K |
Costof Goods And Services Sold | $70K |
Operating Income | -$69M |
Selling General And Administrative | $81M |
Research And Development | $149M |
Operating Expenses | $247M |
Investment Income Net | - |
Net Interest Income | $3.2M |
Interest Income | $6.6M |
Interest Expense | $3.3M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $11M |
Income Before Tax | -$67M |
Income Tax Expense | $3.6M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$71M |
Comprehensive Income Net Of Tax | - |
Ebit | -$64M |
Ebitda | -$53M |
Net Income | -$71M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company headquartered in Abingdon, UK, dedicated to developing innovative T-cell therapies targeting solid tumors. With a focus on harnessing the power of the immune system, Adaptimmune leverages its proprietary SPEAR T-cell platform to design personalized therapies aimed at improving patient outcomes. The company operates primarily within the United States and the United Kingdom, positioning itself at the forefront of immuno-oncology advancements. As it progresses through key clinical trials, Adaptimmune is committed to addressing the significant unmet medical needs of cancer patients through its cutting-edge therapeutic solutions.